Characterization of wound microbes in epidermolysis bullosa: Results from the epidermolysis bullosa clinical characterization and outcomes database.
cultures
epidermolysis bullosa
microbes
resistance
wound
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
14
06
2020
revised:
07
10
2020
accepted:
12
10
2020
pubmed:
29
11
2020
medline:
15
5
2021
entrez:
28
11
2020
Statut:
ppublish
Résumé
Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The EB Clinical Characterization and Outcomes Database serves as a repository of information from EB patients at multiple centers in the United States and Canada. Access to this resource enabled broad-scale analysis of wound cultures. A retrospective analysis of 739 wound cultures from 158 patients from 13 centers between 2001 and 2018. Of 152 patients with a positive culture, Staphylococcus aureus (SA) was recovered from 131 patients (86%), Pseudomonas aeruginosa (PA) from 56 (37%), and Streptococcus pyogenes (GAS) from 34 (22%). Sixty-eight percent of patients had cultures positive for methicillin-sensitive SA, and 47%, methicillin-resistant SA (18 patients had cultures that grew both methicillin-susceptible and methicillin-resistant SA at different points in time). Of 15 patients with SA-positive cultures with recorded mupirocin susceptibility testing, 11 had mupirocin-susceptible SA and 6 patients mupirocin-resistant SA (2 patients grew both mupirocin-susceptible and mupirocin-resistant SA). SCC was reported in 23 patients in the entire database, of whom 10 had documented wound cultures positive for SA, PA, and Proteus species in 90%, 50%, and 20% of cases, respectively. SA and PA were the most commonly isolated bacteria from wounds. Methicillin resistance and mupirocin resistance were reported in 47% and 40% of patients tested, respectively, highlighting the importance of ongoing antimicrobial strategies to limit antibiotic resistance.
Sections du résumé
BACKGROUND/OBJECTIVES
OBJECTIVE
Patients with epidermolysis bullosa (EB) require care of wounds that are colonized or infected with bacteria. A subset of EB patients are at risk for squamous cell carcinoma, and bacterial-host interactions have been considered in this risk. The EB Clinical Characterization and Outcomes Database serves as a repository of information from EB patients at multiple centers in the United States and Canada. Access to this resource enabled broad-scale analysis of wound cultures.
METHODS
METHODS
A retrospective analysis of 739 wound cultures from 158 patients from 13 centers between 2001 and 2018.
RESULTS
RESULTS
Of 152 patients with a positive culture, Staphylococcus aureus (SA) was recovered from 131 patients (86%), Pseudomonas aeruginosa (PA) from 56 (37%), and Streptococcus pyogenes (GAS) from 34 (22%). Sixty-eight percent of patients had cultures positive for methicillin-sensitive SA, and 47%, methicillin-resistant SA (18 patients had cultures that grew both methicillin-susceptible and methicillin-resistant SA at different points in time). Of 15 patients with SA-positive cultures with recorded mupirocin susceptibility testing, 11 had mupirocin-susceptible SA and 6 patients mupirocin-resistant SA (2 patients grew both mupirocin-susceptible and mupirocin-resistant SA). SCC was reported in 23 patients in the entire database, of whom 10 had documented wound cultures positive for SA, PA, and Proteus species in 90%, 50%, and 20% of cases, respectively.
CONCLUSIONS
CONCLUSIONS
SA and PA were the most commonly isolated bacteria from wounds. Methicillin resistance and mupirocin resistance were reported in 47% and 40% of patients tested, respectively, highlighting the importance of ongoing antimicrobial strategies to limit antibiotic resistance.
Identifiants
pubmed: 33247481
doi: 10.1111/pde.14444
pmc: PMC7906915
mid: NIHMS1637008
doi:
Substances chimiques
Anti-Bacterial Agents
0
Mupirocin
D0GX863OA5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
119-124Subventions
Organisme : NICHD NIH HHS
ID : K23 HD091295
Pays : United States
Organisme : Epidermolysis Bullosa Research Partnership
ID : CU16-2131
Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Int J Med Microbiol. 2014 Mar;304(2):195-203
pubmed: 24444717
Antimicrob Agents Chemother. 2015;59(6):3350-6
pubmed: 25824213
Nat Commun. 2015 Jan 09;6:5932
pubmed: 25575023
J Hosp Infect. 2013 Dec;85(4):249-56
pubmed: 24144552
Pediatr Dermatol. 2020 Mar;37(2):326-332
pubmed: 31944391
JAMA Dermatol. 2019 Feb 1;155(2):196-203
pubmed: 30586139
Pediatr Dermatol. 2010 Jan-Feb;27(1):25-8
pubmed: 20199405
J Am Acad Dermatol. 2009 Feb;60(2):203-11
pubmed: 19026465
Adv Skin Wound Care. 2018 Sep;31(9):399-405
pubmed: 29975199
Pediatr Dermatol. 2018 Jan;35(1):92-96
pubmed: 29105824
J Invest Dermatol. 2018 Nov;138(11):2492-2495
pubmed: 29753707
Dermatol Clin. 2010 Apr;28(2):267-9, ix
pubmed: 20447490